Novo Nordisk files MAA for faster-acting insulin aspart in the EU

4 December 2015
novo-nordisk-big

Danish diabetes care giant Novo Nordisk (NOV: N) today announced the submission to the European Medicines Agency of the Marketing Authorization Application (MAA) for the approval of faster-acting insulin aspart.

Faster-acting insulin aspart is a mealtime insulin for improved control of postprandial glucose excursions and has been developed for the treatment of people with type 1 and type 2 diabetes. Faster-acting insulin aspart is insulin aspart (NovoRapid) in a new formulation in which two new excipients have been added to ensure early and fast absorption.

Novo Nordisk expects to file the new drug application for faster-acting insulin aspart with the US Food and Drug Administration before year-end 2015.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical